1247847-78-4
Chemical Structure
Simmitecan hydrochloride
- CAS No.: 1247847-78-4
- Formula:C34H39ClN4O6
- Molecular Weight:635.15
IUPAC Name: (S)-10-allyl-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate hydrochloride
InChIKey: UWNITDCAZZJJFF-GXUZKUJRSA-N
SMILES: [H]Cl.CC[C@]1(O)C(C=C2N3CC4=CC5=C(C=CC(OC(N6CCC(N7CCCCC7)CC6)=O)=C5CC=C)N=C42)=C(COC1=O)C3=O
Biological Activity: Simmitecan hydrochloride is a potent topoisomerase I (TOP1) inhibitor, which is a 9-substituted lipophilic camptothecin (Camptothecin (HY-16560)) derivative. Simmitecan hydrochloride blocks DNA replication and transcription, thereby inducing tumor cell apoptosis by inhibiting the activity of TOP1. Simmitecan hydrochloride can be used for research on cancers such as liver cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Simmitecan hydrochloride | Simmitecan hydrochloride is a potent topoisomerase I (TOP1) inhibitor, which is a 9-substituted lipophilic camptothecin (Camptothecin (HY-16560)) derivative. Simmitecan hydrochloride blocks DNA replication and transcription, thereby inducing tumor cell apoptosis by inhibiting the activity of TOP1. Simmitecan hydrochloride can be used for research on cancers such as liver cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hu ZY, et al. Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals. Acta pharmacologica Sinica. 2013 Nov;34(11):1437-48. [Content Brief]
- [2]. Zhou J, et al. A validated HPLC-MS/MS method for determination of simmitecan and its metabolite chimmitecan in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor. Journal of separation science. 2021 Nov;44(21):3959-3966.
- [3]. Zhang Q, et al. A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor. Frontiers in pharmacology. 2022;13:833583.